Does topical tacrolimus ointment enhance the efficacy of narrowband ultraviolet B therapy in vitiligo? A left-right comparison study

Photodermatology Photoimmunology and Photomedicine

Volumn 26, Issue 5, 2010, Pages 230-234

  Majid, Imran ^a,b  

^a GOVERNMENT MEDICAL COLLEGE   (India)

^b Consulltant Cutis Skin and Laser Institute ^*  (India)

Author keywords

Combination treatment; Narrowband UVB therapy; Tacrolimus; Vitiligo

Indexed keywords

TACROLIMUS;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FACE; FEMALE; HUMAN; LIMB; MAJOR CLINICAL STUDY; MALE; NARROWBAND ULTRAVIOLET B THERAPY; PIGMENTATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCHOOL CHILD; SINGLE BLIND PROCEDURE; SKIN DEFECT; TREATMENT DURATION; TRUNK; ULTRAVIOLET B RADIATION; VITILIGO; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; CHILD; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; OINTMENTS; PROSPECTIVE STUDIES; SINGLE-BLIND METHOD; TACROLIMUS; TREATMENT OUTCOME; ULTRAVIOLET THERAPY; VITILIGO; YOUNG ADULT;

EID: 77956485450     PISSN: 09054383     EISSN: 16000781     Source Type: Journal    
DOI: 10.1111/j.1600-0781.2010.00540.x     Document Type: Article

References (24)

1. Kovacs SO. Vitiligo. J Am Acad Dermatol 1998, 38:647-666.
2. Mattoo SK, Handa S, Kaur I, Gupta N, Malhotra R. Psychiatric morbidity in vitiligo: prevalence and correlates in India. J Eur Acad Dermatol Venereol 2002, 16:573-578.
3. Aghaei S, Sodaifi M, Jafari P, Mazharinia N, Finlay AY. DLQI scores in vitiligo: reliability and validity of the Persian version. BMC Dermatol 2004, 4:8.
4. Njoo MD, Spuls PI, Bos JD, Westerhof W, Bossuyt PM. Nonsurgical repigmentation therapies in vitiligo: meta-analysis of the literature. Arch Dermatol 1998, 134:1532-1540.
5. Scherschun L, Kim JJ, Lim HW. Narrow-band ultraviolet B is a useful and well-tolerated treatment for vitiligo. J Am Acad Dermatol 2001, 44:999-1003.
6. Njoo MD, Boss JD, Westerhof W. Treatment of generalised vitiligo in children with narrow-band (TL-01) UVB radiation therapy. J Am Acad Dermatol 2000, 42:245-253.
7. Goktas EO, Aydin F, Senturk N, Canturk MT, Turanli AY. Combination of narrow-band UVB and topical calcipotriol for the treatment of vitiligo. J Eur Acad Dermatol Venereol 2006, 20:553-557.
8. Ada S, Sahin S, Boztepe G, Karaduman A, Kolemen F. No additional effect of topical calcipotriol on narrow-band UVB phototherapy in patients with generalised vitiligo. Photodermatol Photoimmunol Photomed 2005, 21:79-83.
9. Leone G, Pacifico P, Lacovelli P, Paro Vidolin A, Picardo M. Tacalcitol and narrow-band phototherapy in patients with vitiligo. Clin Exp Dermatol 2006, 31:200-205.
10. Schallreuter KU, Wood JM, Lemke KR, Levenig C. Treatment of vitiligo with a topical application of pseudocatalase and calcium in combination with short-term UVB exposure: a case study on 33 patients. Dermatology 1995, 190:223-229.
11. Esfanduarpour I, Ekhlasi A, Farajedah S, Shamsadini S. The efficacy of 1% pimecrolimus cream plus ultraviolet B in the treatment of vitiligo: a double-blind, placebo-controlled clinical trial. J Dermatolog Treat 2009, 20:14-18.
12. Fai D, Cassano N, Vena GA. Narrowband UVB phototherapy combined with tacrolimus ointment in vitiligo: a review of 110 patients. J Eur Acad Dermatol Venereol 2007, 21:916-920.
13. Mehrabi D, Pandya AG. A randomized, placebo-controlled, double-blind trial comparing narrowband UV-B plus 0.1% tacrolimus ointment with narrowband UV-B plus placebo in the treatment of generalized vitiligo. Arch Dermatol 2006, 142:927-929.
14. Grimes PE, Morris R, Avaniss-Aghajani E, Soriano T, Meraz M, Metzger A. Topical tacrolimus therapy for vitiligo: therapeutic responses and skin messenger RNA expression of proinflammatory cytokines. J Am Acad Dermatol 2004, 51:52-61.
15. Lan CCE, Chen GS, Chiou MH, Wu CS, Chang CH, Yu HS. FK506 promotes melanocyte and melanoblast growth and creates a favourable milieu for cell migration via keratinocytes: possible mechanisms of how tacrolimus ointment induces repigmentation in patients with vitiligo. Br J Dermatol 2005, 153:498-505.
16. Xu AE, Zhang DM, Wei XD. Efficay and safety of tacrolimus cream 0.1% in the treatment of vitiligo. Int J Dermatol 2009, 48:86-90.
17. Grimes PE, Soriano T, Dytoc MT. Topical tacrolimus for repigmentation of vitiligo. J Am Acad Dermatol 2002, 47:789-791.
18. Silverberg B, Lin P, Travis L. Tacrolimus ointment promotes repigmentation of vitiligo in children: a review of 57 cases. J Am Acad Dermatol 2004, 51:760-766.
19. Lepe V, Moncada B, Castanedo-Cazares JP. A double-blind randomized trial of 0·1% tacrolimus vs. 0·05% clobetasol for the treatment of childhood vitiligo. Arch Dermatol 2003, 139:581-585.
20. Hamzavi I, Jain H, McLean D, Shapiro J, Zeng H, Lui H. Parametric modeling of narrowband UV-B phototherapy for vitiligo using a novel quantitative tool: the vitiligo area scoring index. Arch Dermatol 2004, 140:677-683.
21. Kawalek AZ, Spencer JM, Phelps RG. Combined excimer laser and topical tacrolimus for the treatment of vitiligo: a pilot study. Dermatol Surg 2004, 30:130-135.
22. Passeron T, Ostovari N, Zakaria W. Topical tacrolimus and the 308-nm excimer laser: a synergistic combination for the treatment of vitiligo. Arch Dermatol 2004, 140:1065-1069.
23. Yarosh DB, Pena AV, Nay SL, Canning MT, Brown DA. Calcineurin inhibitors decrease DNA repair and apoptosis in human keratinocytes following ultraviolet B radiation. J Invest Dermatol 2000, 125:1020-1025.
24. Gambichler T, Schlafke A, Tomi NS, Othlighaus N, Altmeyer P, Kreuter A. Tacrolimus ointment neither blocks ultraviolet B nor affects expression of thymine dimers and p53 in human skin. J Dermatol Sci 2008, 50:115-122.